Public Health Division
Office of the State Public Health Director
Tina Kotek, Governor
800 NE Oregon St, Ste. 930 | Portland, OR 97232
Voice: 971-673-1222 | Fax: 971-673-1229
email@odhsoha.oregon.gov
www.oregon.gov

Other formats and languages

You can get this document in other languages, large print, braille or a format you prefer free of charge. Contact the Office of the State Public Health Director at email@odhs.oregon.gov or 971-673-1222 (voice/text). We accept all relay calls.

State of Oregon Statewide Standing Order Authorizing Dispensation of Oseltamivir for Novel Influenza A Virus Exposure

Authority and Purpose: Oregon law authorizes the Oregon Public Health Officer to issue a standing order to prescribe a drug to control, prevent, mitigate or treat any infectious or noninfectious disease. 2026 Oregon Law, Chapter 100 (also referred to as SB 1598 (2026)). This standing order acts as a prescription to allow a staff assistant employed by a local public health authority to dispense oseltamivir supplied by Oregon Health Authority as treatment or chemoprophylaxis to any eligible individual under this protocol.

Staff assistants may only perform nonjudgemental dispensing functions under the dispensing physician's license for individuals who meet protocol criteria and must follow all protocol instructions regarding eligibility, screening, labeling, patient education, and record keeping of oseltamivir dispensation.

Applicability: This standing order applies statewide.

Eligibility:

1. **Treatment:** individuals with one or more symptoms compatible with influenza A infection per the Oregon Health Authority Novel Influenza A Investigative Guidelines who meet *any* of the following epidemiologic criteria:
    - Individuals with close contact with a confirmed or probable case of novel influenza A virus per the Oregon Health Authority Novel Influenza A Investigative Guidelines
    - Individuals with a common exposure (e.g., an agricultural fair) with a confirmed or probable case of novel influenza A virus
    - Individuals with direct or indirect contact with animals infected with novel influenza A virus, as determined in collaboration with the Oregon Department of Agriculture
    - Individuals with unprotected direct exposure to novel influenza A virus in a laboratory setting
2. **Chemoprophylaxis:** individuals without symptoms who meet any of the above epidemiologic criteria.

Exclusion criteria:

1. Children under 1 year of age
2. Women who are pregnant or breastfeeding
3. Individuals with known serious hypersensitivity to oseltamivir or any component of the product (refer to packaging)
4. Individuals with medical contraindications to standard dosing:
    - Renal/kidney disease
    - Severe liver disease, including cirrhosis, acute and chronic liver failure, acute and chronic hepatitis, and liver cancer
5. Individuals taking medications which may interact with oseltamivir:
    - Entecavir
    - Methotrexate
    - Pemetrexed
    - Probenecid
    - Tafamidis
    - Trospium
    - Warfarin


Dosing:

Age	Weight	Dose	Number of capsules to dispense (strength)
> 12 years	Not applicable	75 mg by mouth twice daily for 5 days	10 capsules (75 mg)
1–12 years	**40.1 kg or more** (89 lbs. or more)	75 mg by mouth twice daily for 5 days	10 capsules (75 mg)
	23.1–40 kg (51-88 lbs.)	60 mg by mouth twice daily for 5 days	20 capsules (30 mg)
	15.1–23 kg (34–50 lbs.)	45 mg by mouth twice daily for 5 days	10 capsules (45 mg)
	15 kg or less (33 lbs. or less)	30 mg by mouth twice daily for 5 days	10 capsules (30 mg)

Special instructions for dispensation:

1. **Screen for eligibility and exclusion criteria:** when dispensing oseltamivir under this standing order, the staff assistant shall screen for eligibility and exclusion criteria above. If exclusion criteria are identified, the staff assistant must consult their Health Officer or Oregon Health Authority for clinical guidance.
2. **Verify age and weight:** when dispensing oseltamivir under this standing order, the staff assistant shall verify the patient's age and, if age 1-12 years, the patient's weight to select the correct dosage using the chart above.
3. **Labeling:** when dispensing oseltamivir under this standing order, the staff assistant shall label the commercially prepackaged 5-day treatment course of oseltamivir with the following:
   - Name of patient
   - Name and address of dispensing physician (see below)
   - Date of dispensing
4. **Patient education**: provide the patient (or their caregiver) with a copy of the Centers for Disease Control and Prevention *Emergency Use Instructions (EUI) Fact Sheet for Recipients and Caregivers: Oseltamivir to Prevent or Treat Novel Influenza A*. A Spanish version of the fact sheet is available here and limited additional language versions are available here. Ask the patient or caregiver to review the fact sheet and if they have questions regarding oseltamivir. If the patient or caregiver has questions regarding oseltamivir that are not addressed in the fact sheet, the staff assistant must consult their Health Officer or Oregon Health Authority for clinical guidance.

5. **Record keeping:** document eligibility, screening, age, weight, dose, and labeling and patient education information in the individual's relevant Oregon Public Health Epidemiologists' User System (ORPHEUS) record.

Physician Signature: 

Dispensing Physician Name (printed): Melissa Sutton, M.D., M.P.H.

Physician Address: 800 NE Oregon Street, Suite 370, Portland, OR 97232

Under Authority Delegated By: Dean Sidelinger, M.D., M.S.Ed.

Date: November 6, 2026

License Number: MD 196818

NPI: 1154610426